Search

Your search keyword '"Dehm SM"' showing total 106 results

Search Constraints

Start Over You searched for: Author "Dehm SM" Remove constraint Author: "Dehm SM"
106 results on '"Dehm SM"'

Search Results

1. The DNA methylation landscape of advanced prostate cancer

2. A PSMA-targeted Tri-specific Killer Engager enhances NK cell cytotoxicity against prostate cancer.

3. Androgen production, uptake, and conversion (APUC) genes define prostate cancer patients with distinct clinical outcomes.

4. Integrated multi-omics assessment of lineage plasticity in a prostate cancer patient with brain and dural metastases.

5. Computational drug discovery pipelines identify NAMPT as a therapeutic target in neuroendocrine prostate cancer.

6. Integrated analyses highlight interactions between the three-dimensional genome and DNA, RNA and epigenomic alterations in metastatic prostate cancer.

7. Co-occurring BRCA2/SPOP Mutations Predict Exceptional Poly (ADP-ribose) Polymerase Inhibitor Sensitivity in Metastatic Castration-Resistant Prostate Cancer.

8. Androgen receptor and estrogen receptor variants in prostate and breast cancers.

9. Pan-Cancer Interrogation of B7-H3 (CD276) as an Actionable Therapeutic Target Across Human Malignancies.

10. Evolving copy number gains promote tumor expansion and bolster mutational diversification.

11. Stat5 induces androgen receptor ( AR ) gene transcription in prostate cancer and offers a druggable pathway to target AR signaling.

12. Prostate Cancer Progression Relies on the Mitotic Kinase Citron Kinase.

13. Targeting the Androgen Signaling Axis in Prostate Cancer.

14. Fragmentomic analysis of circulating tumor DNA-targeted cancer panels.

15. Co-evolution of AR gene copy number and structural complexity in endocrine therapy resistant prostate cancer.

16. Expression and Therapeutic Targeting of TROP-2 in Treatment-Resistant Prostate Cancer.

17. Basal epithelial cells in prostate development, tumorigenesis, and cancer progression.

18. Computational drug discovery for castration-resistant prostate cancers through in vitro drug response modeling.

19. ALAN is a computational approach that interprets genomic findings in the context of tumor ecosystems.

20. Between here and there: comparing the worry about the pandemic between older Italian international migrants and natives in Switzerland.

21. Molecular Profile Changes in Patients with Castrate-Resistant Prostate Cancer Pre- and Post-Abiraterone/Prednisone Treatment.

22. Opposing transcriptional programs of KLF5 and AR emerge during therapy for advanced prostate cancer.

23. Second-Generation Jak2 Inhibitors for Advanced Prostate Cancer: Are We Ready for Clinical Development?

24. Prospective Evaluation of Clinical Outcomes Using a Multiplex Liquid Biopsy Targeting Diverse Resistance Mechanisms in Metastatic Prostate Cancer.

25. Prostate Cancer Foundation Hormone-Sensitive Prostate Cancer Biomarker Working Group Meeting Summary.

26. AR gene rearrangement analysis in liquid biopsies reveals heterogeneity in lethal prostate cancer.

27. iRGD-liposomes enhance tumor delivery and therapeutic efficacy of antisense oligonucleotide drugs against primary prostate cancer and bone metastasis.

28. A pan-cancer transcriptome analysis of exitron splicing identifies novel cancer driver genes and neoepitopes.

29. Increased transcription and high translation efficiency lead to accumulation of androgen receptor splice variant after androgen deprivation therapy.

30. Androgen receptor variants: RNA-based mechanisms and therapeutic targets.

31. SV-HotSpot: detection and visualization of hotspots targeted by structural variants associated with gene expression.

32. Triple Aberrant Prostate Cancer (TAPC) - Aggregate role of aberrations in TP53 , PTEN and RB1 on ETS gene fusions and prognosis in metastatic castrate resistant prostate cancer.

33. The DNA methylation landscape of advanced prostate cancer.

35. Diverse AR Gene Rearrangements Mediate Resistance to Androgen Receptor Inhibitors in Metastatic Prostate Cancer.

36. Exploitation of CD133 for the Targeted Imaging of Lethal Prostate Cancer.

37. Life in Limbo: Old-Age Transnationalism.

38. PEG10 Promoter-Driven Expression of Reporter Genes Enables Molecular Imaging of Lethal Prostate Cancer.

40. A novel CRISPR-engineered prostate cancer cell line defines the AR-V transcriptome and identifies PARP inhibitor sensitivities.

41. CK2 Pro-Survival Role in Prostate Cancer Is Mediated via Maintenance and Promotion of Androgen Receptor and NFκB p65 Expression.

42. Protein Kinase N1 control of androgen-responsive serum response factor action provides rationale for novel prostate cancer treatment strategy.

43. AR-Variant-Positive CTC: A Surrogate for a Surrogate for Taxane Therapy Outcome?

44. A reciprocal feedback between the PDZ binding kinase and androgen receptor drives prostate cancer.

45. Inhibition of de novo lipogenesis targets androgen receptor signaling in castration-resistant prostate cancer.

46. Androgen Receptor Dependence.

47. Exploiting the transcriptional specificity of the alpha-methylacyl-CoA racemase AMACR promoter for the molecular imaging of prostate cancer.

48. Patient-derived Models of Abiraterone- and Enzalutamide-resistant Prostate Cancer Reveal Sensitivity to Ribosome-directed Therapy.

49. Inhibition of androgen receptor transactivation function by adenovirus type 12 E1A undermines prostate cancer cell survival.

50. Genomic Hallmarks and Structural Variation in Metastatic Prostate Cancer.

Catalog

Books, media, physical & digital resources